ArticleInfection and immunity2015
Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.
Article in Infection and immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 48 citations in OpenAlex.
- Effects of temperature and nutrition stress on Anopheles stephensi, an Indian urban malaria vector.Malaria journal · 2025Article
- Article
- Enrichment of phenotype among biological forms of Anopheles stephensi Liston through establishment of isofemale lines.Parasites & vectors · 2023Article
- Trained immunity: a cutting edge approach for designing novel vaccines against parasitic diseases?Frontiers in immunology · 2023Review
- Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings.Malaria journal · 2022Review
- Harnessing the Algal Chloroplast for Heterologous Protein Production.Microorganisms · 2022Review
- Transmission-Blocking Strategies Against Malaria Parasites During Their Mosquito Stages.Frontiers in cellular and infection microbiology · 2022Review
- Vaccination WithFrontiers in cellular and infection microbiology · 2022Article
- Oral delivery of a functional algal-expressed TGF-β mimic halts colitis in a murine DSS model.Journal of biotechnology · 2021Article
- Global diversity of the gene encoding the Pfs25 protein-a Plasmodium falciparum transmission-blocking vaccine candidate.Parasites & vectors · 2021Article
- Measuring antibody avidity to Plasmodium falciparum merozoite antigens using a multiplex immunoassay approach.Malaria journal · 2020Article
- A Hetero-Multimeric Chitinase-ContainingFrontiers in cellular and infection microbiology · 2020Article
- Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination.PloS one · 2020Article
- Malaria transmission-blocking vaccines: wheat germ cell-free technology can accelerate vaccine development.Expert review of vaccines · 2019Review
- Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25.Nature communications · 2019Article
- Transmission-Blocking Vaccines: Old Friends and New Prospects.Infection and immunity · 2019Review
- A Multi-StageFrontiers in cellular and infection microbiology · 2019Article
- Engineering Strategies in Microorganisms for the Enhanced Production of Squalene: Advances, Challenges and Opportunities.Frontiers in bioengineering and biotechnology · 2019Review
- Correlates of GLA family adjuvants' activities.Seminars in immunology · 2018Review
- Disulfide bond mapping of Pfs25, a recombinant malaria transmission blocking vaccine candidate.Analytical biochemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
A vaccine to prevent the transmission of malaria parasites from infected humans to mosquitoes is an important component for the elimination of malaria in the 21st century, yet it remains neglected as a priority of malaria vaccine development. The lead candidate for Plasmodium falciparum transmission-blocking vaccine development, Pfs25, is a sexual stage surface protein that has been produced for vaccine testing in a variety of heterologous expression systems. Any realistic malaria vaccine will need to optimize proper folding balanced against cost of production, yield, and potentially reactogenic contaminants. Here Chlamydomonas reinhardtii microalga-produced recombinant Pfs25 protein was formulated with four different human-compatible adjuvants (alum, Toll-like receptor 4 [TLR-4] agonist glucopyranosal lipid A [GLA] plus alum, squalene-oil-in-water emulsion, and GLA plus squalene-oil-in-water emulsion) and compared for their ability to induce malaria transmission-blocking antibodies. Alga-produced recombinant Pfs25 plus GLA plus squalene-oil-in-water adjuvant induced the highest titer and avidity in IgG antibodies, measured using alga-produced recombinant Pfs25 as the enzyme-linked immunosorbent assay (ELISA) antigen. These antibodies specifically reacted with the surface of P. falciparum macrogametes and zygotes and effectively prevented parasites from developing within the mosquito vector in standard membrane feeding assays. Alga-produced Pfs25 in combination with a human-compatible adjuvant composed of a TLR-4 agonist in a squalene-oil-in-water emulsion is an attractive new vaccine candidate that merits head-to-head comparison with other modalities of vaccine production and administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.